Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer
Authors:
- 26 February 2021
- journal article
- research article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 37 (4) , 635-642
Abstract
To quantify the association between dose reductions of abiraterone acetate plus prednisone (AAP) or enzalutamide and prostate-specific antigen (PSA) progression in patients with metastatic castrati...Keywords
Funding Information
- Janssen Scientific Affairs, LLC.
This publication has 22 references indexed in Scilit:
- Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized TrialEuropean Urology, 2019
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate CancerNew England Journal of Medicine, 2018
- Efficacy and tolerability of first-line abiraterone + prednisone (ABI) versus enzalutamide (ENZ) for metastatic castration-resistant prostate cancer (mCRPC) in men ≥ 80 years: A retrospective cohort study.Journal of Clinical Oncology, 2018
- Real-world study of enzalutamide and abiraterone acetate (with prednisone) tolerability (REAAcT): Results.Journal of Clinical Oncology, 2018
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerNew England Journal of Medicine, 2015
- Enzalutamide in Metastatic Prostate Cancer before ChemotherapyNew England Journal of Medicine, 2014
- Abiraterone in Metastatic Prostate Cancer without Previous ChemotherapyNew England Journal of Medicine, 2013
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate CancerJournal of Clinical Oncology, 2005